1α,25-Dihydroxyvitamin D 3 (1α,25(OH) 2 D 3 , 1) regulates a variety of biological actions through vitamin D receptor (VDR), including calcium and phosphorus homeostasis, bone remodeling as well as cellular proliferation and differentiation. To enhance its potency and to study the structure and function relationship, we synthesized a series of 1α,25(OH) 2 D 3 analogs with modification at the C-2α position (Figure 1 ). We found that substitution with 2α-methyl, 2α-(3-hydroxypropyl), and 2α-(3-hydroxypropoxy) groups increased the binding affinity for the VDR 2-to 4-fold compared to 1. The crystal structures of the VDR with 2a, 3c, and 4b provide a molecular explanation for the interaction between the 2α-substituents and the water molecules in the ligand binding domain of the VDR. The 2α-terminal hydroxyl group of 3c and 4b replaces one of the water molecules to form hydrogen bonds with the VDR, and additional effect of hydrophobic interaction with elongated 2α-CH 2 groups gave the stronger complex than the VDR-1. Based on accumulated knowledge in VDR agonists 1-5, we synthesized 2α-substituted analogs of 'double side chain' (gemini, 6), 19-norvitamin D 3 (7), TEI-9647 (VDR antagonist 8), 1-alkylated vitamin D 3 (9), and 14-epi-previtamin D 3 (10). Gemini analogs 6a-c showed potent HL-60 cell differentiation activity (1.3-3.8 times compared to 1), and MART-10 (7c) had potent antiproliferative activity on PZ-HPV-7 cells even at 10 2: R = (CH 2 ) n CH 3 2a: n = 0, 2b: n =1, 2c: n = 2, 2d: n = 3 3: R = (CH 2 ) n OH 3a: n = 1, 3b: n = 2, 3c: n = 3, 3d: n = 4 4: R = OCH 2 (CH 2 ) n CH 2 OH 4a: n = 0, 4b: n = 1, 4c: n = 2 5: R = (CH 2 ) n Ph 5a: n = 0, 5b: n = 1, 5c: n = 2 
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